Cognitive Impairment in Patients with Stroke

Abstract

Despite substantial advances in stroke care, vascular cognitive impairment remains a prominent source of disability. Unlike sensorimotor impairments, cognition often continues to decline after stroke. An aging population will increase the prevalence of vascular cognitive impairment, with stroke playing an important role. Ten percent of patients presenting with stroke have pre-stroke dementia; an additional 10% will develop incident dementia with a first stroke, and 30% with a recurrent stroke. While stroke increases the risk of cognitive impairment, the presence of cognitive impairment also impacts acute stroke treatment and increases risk of poor outcome by nearly twofold. There is substantial overlap in the clinical and pathological aspects of vascular and degenerative dementias in many patients. How they relate to one another is controversial. The treatment of vascular cognitive impairment remains supportive, focusing on treating vascular risk factors. Cognitive rehabilitation after stroke is an area of active research, and existing pharmacologic treatments have limited benefit. Heightened awareness of cognitive impairment in the setting of stroke is imperative for prognostication and management, impetus for research and, ultimately, the discovery of efficacious treatments.

Keywords

stroke - cognitive impairment - dementia - imaging - biomarkers - cerebrovascular disease

Publication History

Article published online:
08 January 2021

• References

• 1 Javanshiri K, Waldö ML, Friberg N. et al. Atherosclerosis, hypertension, and diabetes in Alzheimer's disease, vascular dementia, and mixed dementia: prevalence and presentation. J Alzheimers Dis 2018; 66 (04) 1753
• 2 O'Brien JT, Thomas A. Vascular dementia. Lancet 2015; 386 (10004): 1698-1706
• 3 Gorelick PB, Scuteri A, Black SE. et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42 (09) 2672-2713
• 4 Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69 (24) 2197-2204
• 5 Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun study. JAMA 1997; 277 (10) 813-817
• 6 Iadecola C. The pathobiology of vascular dementia. Neuron 2013; 80 (04) 844-866
• 7 Deramecourt V, Slade JY, Oakley AE. et al. Staging and natural history of cerebrovascular pathology in dementia. Neurology 2012; 78 (14) 1043-1050
• 8 Azarpazhooh MR, Avan A, Cipriano LE, Munoz DG, Sposato LA, Hachinski V. Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimers Dement 2018; 14 (02) 148-156
• 9 Savva GM, Stephan BC. Alzheimer's Society Vascular Dementia Systematic Review Group. Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke 2010; 41 (01) e41-e46
• 10 Levine DA, Galecki AT, Langa KM. et al. Trajectory of cognitive decline after incident stroke. JAMA 2015; 314 (01) 41-51
• 11 Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009; 8 (11) 1006-1018
• 12 Rostamian S, Mahinrad S, Stijnen T, Sabayan B, de Craen AJ. Cognitive impairment and risk of stroke: a systematic review and meta-analysis of prospective cohort studies. Stroke 2014; 45 (05) 1342-1348
• 13 Kramarow E, Tejada-Vera B. Dementia mortality in the United States, 2000–2017. National Vital Statistics Reports. In: Hyattsville, MD: US Department of Health and Human Services; 2019
• 14 Benjamin EJ, Muntner P, Alonso A. et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 2019; 139 (10) e56-e528
• 15 Collaborators GD. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18 (01) 88-106
• 16 Patterson C. World Alzheimer Report 2018. The state of the art of dementia research: New frontiers. In: London: Alzheimer's Disease International (ADI); 2018
• 17 Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114 (512) 797-811
• 18 Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1974; 2 (7874): 207-210
• 19 Román GC, Tatemichi TK, Erkinjuntti T. et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43 (02) 250-260
• 20 Diagnostic and Statistical Manual of Mental Disorders. DSM-5. Arlington, VA: American Psychiatric Association; 2013
• 21 Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992; 42 (3 Pt 1): 473-480
• 22 Skrobot OA, Black SE, Chen C. et al; VICCCS group. Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. Alzheimers Dement 2018; 14 (03) 280-292
• 23 Skrobot OA, O'Brien J, Black S. et al; VICCCS group. The vascular impairment of cognition classification consensus study. Alzheimers Dement 2017; 13 (06) 624-633
• 24 Wakisaka Y, Matsuo R, Hata J. et al; Fukuoka Stroke Registry Investigators. Adverse influence of pre-stroke dementia on short-term functional outcomes in patients with acute ischemic stroke: The Fukuoka Stroke Registry. Cerebrovasc Dis 2017; 43 (1-2): 82-89
• 25 Pendlebury ST, Rothwell PM. Risk of recurrent stroke, other vascular events and dementia after transient ischaemic attack and stroke. Cerebrovasc Dis 2009; 27 (Suppl. 03) 1-11
• 26 Pendlebury ST. Dementia in patients hospitalized with stroke: rates, time course, and clinico-pathologic factors. Int J Stroke 2012; 7 (07) 570-581
• 27 Pendlebury ST, Rothwell PM. Oxford Vascular Study. Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study. Lancet Neurol 2019; 18 (03) 248-258
• 28 Zhu L, Fratiglioni L, Guo Z, Winblad B, Viitanen M. Incidence of stroke in relation to cognitive function and dementia in the Kungsholmen Project. Neurology 2000; 54 (11) 2103-2107
• 29 Vicenzini E, Ricciardi MC, Altieri M. et al. Cerebrovascular reactivity in degenerative and vascular dementia: a transcranial Doppler study. Eur Neurol 2007; 58 (02) 84-89
• 30 den Abeelen AS, Lagro J, van Beek AH, Claassen JA. Impaired cerebral autoregulation and vasomotor reactivity in sporadic Alzheimer's disease. Curr Alzheimer Res 2014; 11 (01) 11-17
• 31 Demaerschalk BM, Kleindorfer DO, Adeoye OM. et al; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific Rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2016; 47 (02) 581-641
• 32 Subic A, Cermakova P, Norrving B. et al. Management of acute ischaemic stroke in patients with dementia. J Intern Med 2017; 281 (04) 348-364
• 33 Sepehry AA, Lang D, Hsiung GY, Rauscher A. Prevalence of brain microbleeds in Alzheimer disease: a systematic review and meta-analysis on the influence of neuroimaging techniques. AJNR Am J Neuroradiol 2016; 37 (02) 215-222
• 34 Charidimou A, Shoamanesh A, Wilson D. et al. Cerebral microbleeds and postthrombolysis intracerebral hemorrhage risk updated meta-analysis. Neurology 2015; 85 (11) 927-4
• 35 Dannenberg S, Scheitz JF, Rozanski M. et al. Number of cerebral microbleeds and risk of intracerebral hemorrhage after intravenous thrombolysis. Stroke 2014; 45 (10) 2900-2905
• 36 Powers WJ, Rabinstein AA, Ackerson T. et al; American Heart Association Stroke Council. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018; 49 (03) e46-e110
• 37 Akoudad S, Wolters FJ, Viswanathan A. et al. Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurol 2016; 73 (08) 934-943
• 38 Nogueira RG, Jadhav AP, Haussen DC. et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med 2018; 378 (01) 11-21
• 39 Albers GW, Marks MP, Kemp S. et al; DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med 2018; 378 (08) 708-718
• 40 Goyal M, Menon BK, van Zwam WH. et al; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet 2016; 387 (10029): 1723-1731
• 41 Goldhoorn RB, Verhagen M, Dippel DWJ. et al; MR CLEAN Registry Investigators. Safety and outcome of endovascular treatment in prestroke-dependent patients. Stroke 2018; 49 (10) 2406-2414
• 42 Busl KM, Nogueira RG, Yoo AJ, Hirsch JA, Schwamm LH, Rost NS. Prestroke dementia is associated with poor outcomes after reperfusion therapy among elderly stroke patients. J Stroke Cerebrovasc Dis 2013; 22 (06) 718-724
• 43 Longley V, Peters S, Swarbrick C, Rhodes S, Bowen A. Does pre-existing cognitive impairment impact on amount of stroke rehabilitation received? An observational cohort study. Clin Rehabil 2019; 33 (09) 1492-1502
• 44 Mizrahi EH, Arad M, Adunsky A. Pre-stroke dementia does not affect the post-acute care functional outcome of old patients with ischemic stroke. Geriatr Gerontol Int 2016; 16 (08) 928-933
• 45 Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke 1997; 28 (04) 785-792
• 46 Rasquin SM, Lodder J, Verhey FR. The effect of different diagnostic criteria on the prevalence and incidence of post-stroke dementia. Neuroepidemiology 2005; 24 (04) 189-195
• 47 Alonso A, Knopman DS, Gottesman RF. et al. Correlates of dementia and mild cognitive impairment in patients with atrial fibrillation: the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). J Am Heart Assoc 2017; 6 (07) 6
• 48 Mandzia JL, Smith EE, Horton M. et al. Imaging and baseline predictors of cognitive performance in minor ischemic stroke and patients with transient ischemic attack at 90 days. Stroke 2016; 47 (03) 726-731
• 49 Dhamoon MS, Cheung YK, Gutierrez J. et al. Functional trajectories, cognition, and subclinical cerebrovascular disease. Stroke 2018; 49 (03) 549-555
• 50 Casolla B, Caparros F, Cordonnier C. et al. Biological and imaging predictors of cognitive impairment after stroke: a systematic review. J Neurol 2019; 266 (11) 2593-2604
• 51 Arba F, Quinn T, Hankey GJ, Ali M, Lees KR, Inzitari D. VISTA Collaboration. Cerebral small vessel disease, medial temporal lobe atrophy and cognitive status in patients with ischaemic stroke and transient ischaemic attack. Eur J Neurol 2017; 24 (02) 276-282
• 52 Sagnier S, Catheline G, Dilharreguy B. et al. Admission brain cortical volume: an independent determinant of poststroke cognitive vulnerability. Stroke 2017; 48 (08) 2113-2120
• 53 Sivakumar L, Riaz P, Kate M. et al. White matter hyperintensity volume predicts persistent cognitive impairment in transient ischemic attack and minor stroke. Int J Stroke 2017; 12 (03) 264-272
• 54 Yatawara C, Ng KP, Chander R, Kandiah N. Associations between lesions and domain-specific cognitive decline in poststroke dementia. Neurology 2018; 91 (01) e45-e54
• 55 Paradise MB, Shepherd CE, Wen W, Sachdev PS. Neuroimaging and neuropathology indices of cerebrovascular disease burden: a systematic review. Neurology 2018; 91 (07) 310-320
• 56 Ter Telgte A, van Leijsen EMC, Wiegertjes K, Klijn CJM, Tuladhar AM, de Leeuw FE. Cerebral small vessel disease: from a focal to a global perspective. Nat Rev Neurol 2018; 14 (07) 387-398
• 57 Makin SD, Turpin S, Dennis MS, Wardlaw JM. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. J Neurol Neurosurg Psychiatry 2013; 84 (08) 893-900
• 58 Edwards JD, Jacova C, Sepehry AA, Pratt B, Benavente OR. A quantitative systematic review of domain-specific cognitive impairment in lacunar stroke. Neurology 2013; 80 (03) 315-322
• 59 Arba F, Quinn TJ, Hankey GJ. et al; VISTA Collaboration. Enlarged perivascular spaces and cognitive impairment after stroke and transient ischemic attack. Int J Stroke 2018; 13 (01) 47-56
• 60 Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology 2014; 83 (14) 1228-1234
• 61 Huijts M, Duits A, van Oostenbrugge RJ, Kroon AA, de Leeuw PW, Staals J. Accumulation of MRI markers of cerebral small vessel disease is associated with decreased cognitive function. A study in first-ever lacunar stroke and hypertensive patients. Front Aging Neurosci 2013; 5: 72
• 62 Wardlaw JM, Smith EE, Biessels GJ. et al; Standards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol 2013; 12 (08) 822-838
• 63 Du J, Wang Y, Zhi N. et al. Structural brain network measures are superior to vascular burden scores in predicting early cognitive impairment in post stroke patients with small vessel disease. Neuroimage Clin 2019; 22: 101712
• 64 Patel B, Lawrence AJ, Chung AW. et al. Cerebral microbleeds and cognition in patients with symptomatic small vessel disease. Stroke 2013; 44 (02) 356-361
• 65 Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970; 11 (03) 205-242
• 66 Schneider JA, Wilson RS, Cochran EJ. et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003; 60 (07) 1082-1088
• 67 Marchina S, Zhu LL, Norton A, Zipse L, Wan CY, Schlaug G. Impairment of speech production predicted by lesion load of the left arcuate fasciculus. Stroke 2011; 42 (08) 2251-2256
• 68 Munsch F, Sagnier S, Asselineau J. et al. Stroke location is an independent predictor of cognitive outcome. Stroke 2016; 47 (01) 66-73
• 69 Chaudhari TS, Verma R, Garg RK, Singh MK, Malhotra HS, Sharma PK. Clinico-radiological predictors of vascular cognitive impairment (VCI) in patients with stroke: a prospective observational study. J Neurol Sci 2014; 340 (1-2): 150-158
• 70 Grysiewicz R, Gorelick PB. Key neuroanatomical structures for post-stroke cognitive impairment. Curr Neurol Neurosci Rep 2012; 12 (06) 703-708
• 71 Zhao L, Biesbroek JM, Shi L. et al. Strategic infarct location for post-stroke cognitive impairment: a multivariate lesion-symptom mapping study. J Cereb Blood Flow Metab 2018; 38 (08) 1299-1311
• 72 van der Flier WM, Skoog I, Schneider JA. et al. Vascular cognitive impairment. Nat Rev Dis Primers 2018; 4: 18003
• 73 Wallin A, Kapaki E, Boban M. et al. Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - a consensus report. BMC Neurol 2017; 17 (01) 102
• 74 Kliper E, Bashat DB, Bornstein NM. et al. Cognitive decline after stroke: relation to inflammatory biomarkers and hippocampal volume. Stroke 2013; 44 (05) 1433-1435
• 75 Tiedt S, Duering M, Barro C. et al. Serum neurofilament light: a biomarker of neuroaxonal injury after ischemic stroke. Neurology 2018; 91 (14) e1338-e1347
• 76 Duering M, Konieczny MJ, Tiedt S. et al. Serum neurofilament light chain levels are related to small vessel disease burden. J Stroke 2018; 20 (02) 228-238
• 77 Zhong C, Bu X, Xu T. et al. Serum matrix metalloproteinase-9 and cognitive impairment after acute ischemic stroke. J Am Heart Assoc 2018; 7 (01) 7
• 78 Hankey GJ, Ford AH, Yi Q. et al; VITATOPS Trial Study Group. Effect of B vitamins and lowering homocysteine on cognitive impairment in patients with previous stroke or transient ischemic attack: a prespecified secondary analysis of a randomized, placebo-controlled trial and meta-analysis. Stroke 2013; 44 (08) 2232-2239
• 79 Markus HS, Schmidt R. Genetics of vascular cognitive impairment. Stroke 2019; 50 (03) 765-772
• 80 Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. CADASIL. Lancet Neurol 2009; 8 (07) 643-653
• 81 Verdura E, Hervé D, Scharrer E. et al. Heterozygous HTRA1 mutations are associated with autosomal dominant cerebral small vessel disease. Brain 2015; 138 (Pt 8): 2347-2358
• 82 Brainin M, Tuomilehto J, Heiss WD. et al. Post-stroke cognitive decline: an update and perspectives for clinical research. Eur J Neurol 2015; 22: 229-238 , e213–226
• 83 Allan LM, Rowan EN, Firbank MJ. et al. Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors. Brain 2011; 134 (Pt 12): 3716-3727
• 84 Portegies ML, Wolters FJ, Hofman A, Ikram MK, Koudstaal PJ, Ikram MA. Prestroke vascular pathology and the risk of recurrent stroke and poststroke dementia. Stroke 2016; 47 (08) 2119-2122
• 85 Gupta A, Iadecola C. Impaired Aβ clearance: a potential link between atherosclerosis and Alzheimer's disease. Front Aging Neurosci 2015; 7: 115
• 86 Di Marco LY, Venneri A, Farkas E, Evans PC, Marzo A, Frangi AF. Vascular dysfunction in the pathogenesis of Alzheimer's disease--A review of endothelium-mediated mechanisms and ensuing vicious circles. Neurobiol Dis 2015; 82: 593-606
• 87 Yarchoan M, Xie SX, Kling MA. et al. Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias. Brain 2012; 135 (Pt 12): 3749-3756
• 88 Dong Y, Xu J, Chan BP. et al. The Montreal Cognitive Assessment is superior to National Institute of Neurological Disease and Stroke-Canadian Stroke Network 5-minute protocol in predicting vascular cognitive impairment at 1 year. BMC Neurol 2016; 16: 46
• 89 Dregan A, Wolfe CD, Gulliford MC. Does the influence of stroke on dementia vary by different levels of prestroke cognitive functioning?: A cohort study. Stroke 2013; 44 (12) 3445-3451
• 90 Reitz C, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM. Prestroke cognitive performance, incident stroke, and risk of dementia: the Rotterdam Study. Stroke 2008; 39 (01) 36-41
• 91 Mok VC, Lam BY, Wong A, Ko H, Markus HS, Wong LK. Early-onset and delayed-onset poststroke dementia - revisiting the mechanisms. Nat Rev Neurol 2017; 13 (03) 148-159
• 92 Alladi S, Bak TH, Mekala S. et al. Impact of bilingualism on cognitive outcome after stroke. Stroke 2016; 47 (01) 258-261
• 93 Nijsse B, Visser-Meily JM, van Mierlo ML, Post MW, de Kort PL, van Heugten CM. Temporal evolution of poststroke cognitive impairment using the Montreal Cognitive Assessment. Stroke 2017; 48 (01) 98-104
• 94 Sivakumar L, Kate M, Jeerakathil T, Camicioli R, Buck B, Butcher K. Serial Montreal cognitive assessments demonstrate reversible cognitive impairment in patients with acute transient ischemic attack and minor stroke. Stroke 2014; 45 (06) 1709-1715
• 95 Oldenbeuving AW, de Kort PL, Jansen BP, Algra A, Kappelle LJ, Roks G. Delirium in the acute phase after stroke: incidence, risk factors, and outcome. Neurology 2011; 76 (11) 993-999
• 96 Levine DA, Wadley VG, Langa KM. et al. Risk factors for poststroke cognitive decline: the REGARDS study (Reasons for Geographic and Racial Differences in Stroke). Stroke 2018; 49 (04) 987-994
• 97 Zheng F, Yan L, Zhong B, Yang Z, Xie W. Progression of cognitive decline before and after incident stroke. Neurology 2019; 93 (01) e20-e28
• 98 Gaynor E, Rohde D, Large M. et al. Cognitive impairment, vulnerability, and mortality post ischemic stroke: a five-year follow-up of the Action on Secondary Prevention Interventions and Rehabilitation in Stroke (ASPIRE-S) Cohort. J Stroke Cerebrovasc Dis 2018; 27 (09) 2466-2473
• 99 Oksala NK, Jokinen H, Melkas S. et al. Cognitive impairment predicts poststroke death in long-term follow-up. J Neurol Neurosurg Psychiatry 2009; 80 (11) 1230-1235
• 100 Hasan TF, Barrett KM, Brott TG. et al. Severity of white matter hyperintensities and effects on all-cause mortality in the Mayo Clinic Florida Familial Cerebrovascular Diseases Registry. Mayo Clin Proc 2019; 94 (03) 408-416
• 101 McGovern A, Pendlebury ST, Mishra NK, Fan Y, Quinn TJ. Test Accuracy of informant-based cognitive screening tests for diagnosis of dementia and multidomain cognitive impairment in stroke. Stroke 2016; 47 (02) 329-335
• 102 Hachinski V, Iadecola C, Petersen RC. et al. National institute of neurological disorders and stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006; 37 (09) 2220-2241
• 103 Van Heugten CM, Walton L, Hentschel U. Can we forget the Mini-Mental State Examination? A systematic review of the validity of cognitive screening instruments within one month after stroke. Clin Rehabil 2015; 29 (07) 694-704
• 104 Quinn TJ, Elliott E, Langhorne P. Cognitive and mood assessment tools for use in stroke. Stroke 2018; 49 (02) 483-490
• 105 Demeyere N, Riddoch MJ, Slavkova ED, Bickerton WL, Humphreys GW. The Oxford Cognitive Screen (OCS): validation of a stroke-specific short cognitive screening tool. Psychol Assess 2015; 27 (03) 883-894
• 106 Demeyere N, Riddoch MJ, Slavkova ED. et al. Domain-specific versus generalized cognitive screening in acute stroke. J Neurol 2016; 263 (02) 306-315
• 107 Mancuso M, Demeyere N, Abbruzzese L. et al; Italian OCS Group. Using the Oxford Cognitive Screen to detect cognitive impairment in stroke patients: a comparison with the Mini-Mental State Examination. Front Neurol 2018; 9: 101
• 108 Mellon L, Brewer L, Hall P, Horgan F, Williams D, Hickey A. ASPIRE-S study group. Cognitive impairment six months after ischaemic stroke: a profile from the ASPIRE-S study. BMC Neurol 2015; 15: 31
• 109 McKevitt C, Fudge N, Redfern J. et al. Self-reported long-term needs after stroke. Stroke 2011; 42 (05) 1398-1403
• 110 Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet 2011; 377 (9778): 1693-1702
• 111 Gillespie DC, Bowen A, Chung CS, Cockburn J, Knapp P, Pollock A. Rehabilitation for post-stroke cognitive impairment: an overview of recommendations arising from systematic reviews of current evidence. Clin Rehabil 2015; 29 (02) 120-128
• 112 Merriman NA, Sexton E, McCabe G. et al. Addressing cognitive impairment following stroke: systematic review and meta-analysis of non-randomised controlled studies of psychological interventions. BMJ Open 2019; 9 (02) e024429
• 113 Bath PM, Scutt P, Blackburn DJ. et al; PODCAST Trial Investigators. Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the Pilot ‘Prevention of Decline in Cognition after Stroke Trial’ (PODCAST) randomised controlled trial. PLoS One 2017; 12 (01) e0164608
• 114 Douiri A, McKevitt C, Emmett ES, Rudd AG, Wolfe CD. Long-term effects of secondary prevention on cognitive function in stroke patients. Circulation 2013; 128 (12) 1341-1348
• 115 Román GC, Salloway S, Black SE. et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010; 41 (06) 1213-1221
• 116 Wilkinson D, Doody R, Helme R. et al; Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61 (04) 479-486
• 117 Black S, Román GC, Geldmacher DS. et al; Donepezil 307 Vascular Dementia Study Group. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34 (10) 2323-2330
• 118 Dichgans M, Markus HS, Salloway S. et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol 2008; 7 (04) 310-318
• 119 Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C. GAL-INT-26 Study Group. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007; 69 (05) 448-458
• 120 Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359 (9314): 1283-1290
• 121 Farooq MU, Min J, Goshgarian C, Gorelick PB. Pharmacotherapy for vascular cognitive impairment. CNS Drugs 2017; 31 (09) 759-776
• 122 Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; (01) CD005593
• 123 Guekht A, Skoog I, Edmundson S, Zakharov V, Korczyn AD. ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): a randomized controlled trial to assess the efficacy of Actovegin in poststroke cognitive impairment. Stroke 2017; 48 (05) 1262-1270